This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CXC chemokine receptor 2 (CXCR2; IL8RB)	<p>Mouse studies suggest CXCR2 antagonists could help treat cancer. In mouse models of inflammation-driven intestinal and skin tumors, knockout of <i>Cxcr2</i> decreased tumorigenesis compared with normal <i>Cxcr2</i> expression. In a mouse model of primary benign intestinal adenomas, a pepducin against <i>Cxcr2</i> decreased tumorigenesis compared with a nontargeting pepducin. Next steps could include clinical testing of CXCR2 antagonists in cancer models. At least six companies have CXCR2 antagonists in Phase II testing or earlier to treat pulmonary and transplant-related indications.</p> <p>SciBX 5(37); doi:10.1038/scibx.2012.978 Published online Sept. 20, 2012</p>	Patent and licensing status unavailable	<p>Jamieson, T. <i>et al.</i> <i>J. Clin. Invest.</i>; published online Aug. 27, 2012; doi:10.1172/JCI61067</p> <p>Contact: Thomas Jamieson, The Beatson Institute for Cancer Research, Glasgow, U.K. e-mail: t.jamieson@beatson.gla.ac.uk</p>